All answers

•Starts plasma exchange (x3) and steroids
•LDH decrease, but platelets and creatinine remain abnormal
•Shiga toxin: negative
•No evident underlying causes – normal B12
•ADAMTS13: 45%
What do we do next?


Start complement inhibition (eculizumab/ravulizumab)
Start caplacizumab and rituximab, without plasma exchange

Map: TMA (792)
Node: 16362
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • Scenariul cu mai mulți copii.
  • Folosește regula binomului
  • Înmulțiți ¼ cu 4
  • La imagen A es de SEM y la imagen B es de TEM
  • Experimental Setup #1
  • Înmulțiți ¼ cu sine însuși pentru primul copil și listați restul ca neafectate
  • Descripción 1
  • Considerații suplimentare
  • Decontamination and resetting the experiment
  • Opción 1
  • No, although the patient and caregiver consent, the patient has no known mutation and complete clinical response
  • Start complement inhibition (eculizumab/ravulizumab)
  • Opción 2
  • All answers

Reminder

FINISH

Time is up